

**Equitable access**


**Affordability and pricing**

**Health system resilience**

**Ethical business culture**

**Inclusion and diversity**

**Workforce safety and health**



**Ambition Zero Carbon**

**Product sustainability**

**Natural resources**

**We value the diverse perspectives of internal and external stakeholders, which help to shape our sustainability strategy and guide its implementation.**

We welcome transparent dialogue via a range of communication channels — online, face to face and in groups.

### Materiality assessment

In 2021 we refreshed our previous materiality assessment, which guides our sustainability strategy by identifying the issues that matter most to AstraZeneca and our stakeholders, and shows where we can have the most positive impact. We also assess our strategy against emerging trends and through what we learn from all our stakeholder engagements.

In collaboration with an independent consultancy, and with the directional guidance of our Sustainability Advisory Board (SAB), our 2021 materiality assessment refined how we define our priorities and broadened the scope of nine focus areas. Each material focus area is detailed in our 2021 Sustainability Report, along with the relevant targets and goals, illustrated by examples of sustainability in action from our 2021 activities. Following this exercise, it was agreed that the SAB had fulfilled its remit.

### Materiality Map

